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Introduction: We designed this phase II trial to evaluate the
efficacy and safety of weekly paclitaxel in combination with
monthly carboplatin as first-line treatment in elderly patients with
advanced non-small cell lung cancer (NSCLC).
Methods: Main eligibility criteria were histologically or cytologi-
cally proven stage IIIB or IV NSCLC, age 70 years, Eastern
Cooperative Oncology Group performance status 0-2, and measur-
able disease. The 4-week–based chemotherapy regimen consisted of
carboplatin infusion (area under the concentration-time curve 6
mg/ml-1/min) on day 1 and paclitaxel 90 mg/m2 as a 1-hour infusion
on days 1, 8, and 15. Tumor response was evaluated using Response
Evaluation Criteria in Solid Tumors criteria, and symptoms were
evaluated using the Lung Cancer Symptoms Scale. Analyses were
performed on an intention-to-treat basis.
Results: From February 2002 to August 2003, 51 patients (median
age, 74 years) participated in the study. One complete and 21 partial
responses were reported by the independent review committee,
leading to an intention-to-treat objective response rate of 43% (95%
confidence interval, 30–57%). The median progression-free and
overall survivals were 7.5 (95% confidence interval, 6.2–9.4) and
13.6 (95% confidence interval, 7.5–17) months, respectively. Lon-
gitudinal evaluation of the Lung Cancer Symptoms Scale demon-
strated lack of quality of life modification during the treatment
period. Neurotoxicity was mild to moderate, with 6% of patients
suffering from a grade 3 or 4 neuropathy. Myelosuppression was the
main toxicity; 39% of patients experienced grade 3 or 4 neutropenia,
18% experienced grade 3 anemia, and 8% experienced grade 3 or 4
thrombocytopenia. There was no treatment-related death.
Conclusions: The combination of weekly paclitaxel 90 mg/m2
administered on days 1, 8, and 15 plus monthly carboplatin area
under the curve 6 on day 1 of a 4-week cycle was feasible and active
as a first-line treatment for elderly patients with NSCLC with a good
safety profile. These results deserve further analysis to compare the
standard care for these patients (monotherapies) with this doublet.
Key Words: Non-small cell lung cancer, Efficacy/safety ratio,
Paclitaxel, Carboplatin, Elderly, Phase II, Quality of life.
(J Thorac Oncol. 2006;1: 328–334)
Lung cancer is the major cause of cancer-related death inthe elderly population. More than one half of patients with
lung cancer are older than 60 years at diagnosis, and one third
of all patients with non-small cell lung cancer (NSCLC) are
older than 70 years.1 A study of survival among patients with
lung cancer in European countries (EUROCARE program)
showed 1-year and 5-year overall survival of 28% and 7%,
respectively, in patients more than 70 years old.2 Comorbidi-
ties affecting the elderly population and limiting the use of
standard treatments could be one of the reasons explaining
this low survival rate. Therefore, the development of specific
care for this patient population is needed.
Platinum-based combinations have been accepted
worldwide as regimens to treat advanced NSCLC because of
a clear survival improvement using various platinum-based
doublets compared with best supportive care only.3 However,
elderly patients are often unsuitable for cisplatin-based che-
motherapy because of the physiological reduction of func-
tional reserves. Some of the more recently developed chemo-
therapeutic agents are better tolerated than the older cisplatin-
based combinations, with favorable therapeutic indices in the
elderly. Paclitaxel, the prototypical taxane, induced a 20%
response rate in patients with advanced NSCLC4,5 and has
been associated with an improvement in 1-year survival in
phase III trials.6 Even if there is a concern regarding the
equivalence in terms of efficacy,7 the substitution of cisplatin
by carboplatin in a doublet regimen offers patients a clear
reduction in risk of renal impairment and neurological toxic-
ity when it is administered according to a projected area
under the concentration-time curve (AUC).
*Department of Thoracic Oncology, Montpellier Academic Hospital, Mont-
pellier; †Department of Chest Medicine, Tenon Academic Hospital,
Paris; ‡Department of Chest Medicine, Strasbourg Academic Hospital,
Strasbourg; §Department of Chest Medicine, Besanc¸on Academic Hos-
pital, Besanc¸on; Department of Chest Medicine, Belfort Hospital, Bel-
fort; ¶Department of Chest Medicine, Franc¸ois Baclesse, Cancer Insti-
tute, Caen; **Department of Chest Medicine, Vesoul Hospital, Vesoul;
††Department of Chest Medicine, Annecy Hospital, Annecy; ‡‡Bristol-
Myers Squibb, Rueil-Malmaison, France.
Address for correspondence: Jean-Louis Pujol, M.D., Hoˆpital Arnaud de
Villeneuve, Avenue du Doyen Giraud, 34295 Montpellier Cedex 5,
France. E-mail: jl-pujol@chu-montpellier.fr
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0104-0328
Journal of Thoracic Oncology • Volume 1, Number 4, May 2006328
When paclitaxel and carboplatin are combined every 3
weeks, response rates among patients with advanced NSCLC
ranged from 27% to 41%, median survival ranged from 10 to
12 months, and 1-year survival ranged from 30% to 54%
without major toxicity.8–10 Paclitaxel 200 mg/m2 and carbo-
platin AUC 6 mg/ml-1/min given every 21 days as first-line
chemotherapy were evaluated retrospectively in elderly pa-
tients (aged 70 years) with NSCLC and showed a good
response rate and acceptable toxicity.11 However, this report
included only a subgroup of a larger study that was not
specifically designed for the elderly. No study had been
designed to evaluate the carboplatin-paclitaxel doublet in the
elderly population.
Weekly exposure to paclitaxel might offer higher anti-
tumor activity compared with the paclitaxel every-3-weeks
schedule because it is thought to reduce the chance of
resistant cell clone emergence by shortening the intervals
between administrations. According to a phase I-II study in
NSCLC, weekly paclitaxel is well tolerated and yields a good
therapeutic index that compares well with the standard sched-
ule.12 In a recent randomized phase II study comparing three
different schedules of weekly paclitaxel and carboplatin (de-
livered on either a weekly or monthly schedule), the optimal
efficacy/safety profile was observed with the following regi-
men: paclitaxel 100 mg/m2 given on days 1, 8, and 15 and
carboplatin AUC 6 mg/ml-1/min on day 1 of a 28-day cycle.13
The acceptable tolerance of this schedule makes it deserving
of evaluation among patients with NSCLC with unfavorable
conditions at presentation, such as are frequently observed in
the elderly.
In this phase II study, we aimed to determine the
efficacy and safety of weekly paclitaxel combined with
monthly carboplatin as first-line treatment among elderly
patients with advanced NSCLC. Paclitaxel was used at the
dose of 90 mg/m2 on days 1, 8, and 15 in combination with
carboplatin AUC 6 mg/ml-1/min on day 1 of a 28-day cycle.
PATIENTS AND METHODS
Patient Eligibility
Patients older than 70 years with chemonaive histolog-
ically or cytologically proven stage IIIB or IV NSCLC not
suitable for surgery were eligible. Patients with stage IIIB
were eligible whether their disease was advanced so that
radiotherapy could not be given at curative intent. Patients
with local or metastatic failure after surgery and/or radiother-
apy were eligible for the study if at least one indicator lesion
could be measured according to Response Evaluation Criteria
in Solid Tumors (RECIST) criteria.14 The indicator lesion had
to be outside a previously irradiated area. Other eligibility
criteria included Eastern Cooperative Oncology Group
(ECOG) performance status (PS) between 0 and 2 and an
estimated life expectancy of at least 12 weeks. Patients were
required to have adequate bone marrow reserve (neutrophils
2/109/L, platelets 125/109/L) and satisfactory hepatic
(bilirubin 1.5 times the upper institutional limits of normal
[ULN], alanine transferase 2.5 UNL or 5 UNL in the
presence of hepatic metastases) and renal functions (serum
creatinine 1.5 UNL and creatinine clearance 60 ml/min).
In addition, patients had to have recovered from recent
surgery and radiation therapy (with at least 1 week elapsed
from the time of a minor surgery and at least 3 weeks from
major surgery and radiotherapy). Non-eligibility criteria con-
sisted of the presence of symptomatic central nervous system
metastases, evidence of any peripheral neuropathy, prior
allergic reactions to drugs containing Cremophor (BASF
Aktiengesellschaft, Ludwigshafen, Germany), active infec-
tion, or prior malignant disease (except well-controlled basal
cell skin cancer or in situ cervix carcinoma). Written in-
formed consent was obtained from every patient before study
entry. The study was conducted in accordance with good
clinical practices and was approved by the local ethics com-
mittee.
Treatment Plan
Eligible patients were treated with paclitaxel plus car-
boplatin for up to six cycles, except in the case of tumor
progression, inter-current disease, unacceptable toxicity, or
patient’s refusal to continue. The 4-week–based chemother-
apy regimen consisted of a carboplatin (Paraplatin; Bristol-
Myers Squibb, Rueil-Malmaison, France) infusion given on
day 1 with AUC 6 mg/ml-1/min as calculated using Calvert’s
formula, and paclitaxel (Taxol; Bristol-Myers Squibb) 90
mg/m2 as a 1-hour infusion on days 1, 8, and 15. The
following premedications for prophylaxis of hypersensitivity
reactions were administered 30 minutes to 1 hour before
paclitaxel: (a) dexamethasone 10 mg IV; (b) dexchlophenira-
mine 5 mg IV; and (c) cimetidine 300 mg IV or ranitine 50
mg IV. A cycle restarted at day 28 pending hematological
recovery; i.e., the absolute neutrophil count 1.5/109/L and
platelets 100/109/L, and return to grade 0 or 1 for non-
hematological toxicity. If one or more of these conditions was
not met, then a 1- to 2-week delay was allowed for recovery.
Dose reductions were required for both paclitaxel and carbo-
platin pending the occurrence of one of the following toxic-
ities: grade 4 neutropenia lasting 7 days or more during the
previous cycle; grade 3 or 4 febrile neutropenia; grade 3 or 4
infection with neutropenia; grade 4 anemia or thrombocyto-
penia or bleeding requiring transfusion; grade 2 neurotoxic-
ity; and any grade 3 non-hematological toxicity. Study
drugs were discontinued in the case of grade 2 hearing
disorders or renal toxicity (carboplatin); grade 3 hypersen-
sitivity reactions (paclitaxel) and grade  2 cardiotoxicity; or
hepatoxicity and grade  3 pain or neurotoxicity (both
drugs). Paclitaxel was administered on days 8 and 15 depend-
ing on hematological recovery; i.e., the absolute neutrophil
count 1.5/109/L and platelets 100/109/L, and return to
grade 0 or 1 for non-hematological toxicity.
Study Assessments
Pretreatment evaluation included a complete medical
history and clinical examination with tumor measurements
(imaging studies and physical examination when appropri-
ate), electrocardiogram, chest radiograph, appropriate radio-
logical tests, concomitant treatments, PS, quality of life
(QoL) according to the Lung Cancer Symptoms Scale
(LCSS), and hematological and biochemical profiles. Tumor
measurements were performed every other cycle during the
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study and every 3 months subsequently until progression.
LCSS was evaluated at baseline and before each cycle.
During the study, complete blood counts including a platelet
and leukocyte differential count were performed weekly, and
blood chemistry was also analyzed before each cycle.
Response and Toxicity Criteria
Patients were evaluated for response and progression
according to the RECIST criteria.14 Changes in only the
largest diameter (unidimensional measurement) of the tumor
lesions are used in the RECIST. A minimal duration of 4
weeks was required to document a response, and the best
response was recorded for each patient. Clinical responses
were reviewed by independent experts. Time to response was
defined as the time from the first dose of study drug until the
first objective status assessment of partial/complete response.
Response duration was measured from the time measurement
criteria for partial/complete response was first registered until
the first time that recurrent or progressive disease was objec-
tively documented. Progression-free survival was defined as
the time from the date of registration until the date of
progression or death. Survival was defined as the time from
the date of registration (informed consent date) to the date of
death.
Toxicity, graded according to the National Cancer In-
stitute Common Toxicity Criteria (NCI-CTC, version 2.0),
was assessed by clinical examination and biological tests
before each cycle of chemotherapy.15
Lung Cancer Symptoms Scale
This scale is specifically designed for research and
clinical use in lung cancer populations and focuses primarily
on the physical dimension, particularly symptoms and symp-
tomatic distress specific to lung cancer and subsequent
QoL.16 It consists of two scales: one completed by the patient
(nine items as visual analogue scales from 0 to 100) and one
for health care professionals (six items as five-point categor-
ical scales) to provide context. An average of the aggregate
score of all nine items was used for a total score for patient
scale.
Statistical Considerations
The primary end point of the study was the objective
response rate (ORR) of the combination of weekly paclitaxel
with monthly carboplatin in elderly patients with NSCLC. A
modified Simon optimal two-stage design was used to test
whether the ORR was of clinical interest.17 A minimum of 19
evaluable patients and a maximum of 44 evaluable patients
had to be included in the study. Taking into account that a
20% response rate is usually observed in chemotherapies for
elderly patients (e.g., single-drug chemotherapy), a response
rate of at least 35% was considered of clinical interest.
Estimates of median time to response, duration of response,
progression-free survival, and overall survival with their 95%
confidence intervals (CI) were calculated using the Kaplan-
Meier product-limit method. For toxicity analyses, the worst
grade for each patient in all cycles of chemotherapy was used.
Actual dose intensity for each drug was defined as the ratio of
the administered dose per unit of time to the planned dose per
unit of time.18 For each patient, the dose intensity was
calculated taking into account the actual time of treatment
plus 4 weeks. The relative dose intensity of paclitaxel by
patient was calculated as the dose intensity in mg/m2/week
actually received divided by the planned dose intensity. The
planned dose intensity was 67.5 mg/m2/week. The relative
dose intensity of carboplatin by patient was calculated as the
dose intensity in AUC/week actually received divided by the
planned dose intensity in AUC/week. The planned dose
intensity was AUC 1.5 mg/ml-1/min/week.
All analyses were performed on an intention-to-treat
(ITT) basis. The statistical analyses were performed using
SAS software, version 8.2 (SAS Institute Inc, Cary, NC).
RESULTS
Patients
From February 2002 to March 2003, 51 elderly patients
with NSCLC from eight French centers were included in the
study. Patients’ characteristics at baseline are summarized in
Table 1. Most patients were male, and the median age was 74
years (range, 69 to 88 years). One 69-year-old patient was
TABLE 1. Baseline patient characteristics
Number of
patients (%)
Age (yr)
Median 74.0
Range 69–88
Mean (SD) 75.2 (4.7)
Sex
Male 38 75
Female 13 25
ECOG PS
0 15 29
1 31 61
2 5 10
Histology
Squamous cell carcinoma 18 35
Adenocarcinoma 27 53
Large cell carcinoma 3 6
Other 3 6
Stage
IIIB 9 18
IV 42 82
Metastatic sites
0 8 16
1 25 49
2 15 29
4 2 4
Missing 1 2
Prior surgery 13 25
Time from last surgery to
informed consent (mo)
Median 1.3
Range 0.1–37.8
n  51. ECOG, Eastern Cooperative Oncology Group; PS, performance status.
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accrued into this study and has been considered a protocol
deviation at registration. ECOG PS was 0 or 1 for most
patients. Adenocarcinoma and squamous cell carcinoma were
the most frequent histologies, and most patients had stage IV
disease.
Treatment Exposure
A total of 209 cycles were administered in 51 patients
with a median number of four cycles per patient (range, one
to six cycles). Overall, 174 cycles (83%) were completed.
Paclitaxel was not administered on days 8 and 15 for eight
cycles (4%), and on day 15 for 27 cycles (13%). Of 584
infusions, 26 (4%) were delayed because of hematological
toxicity (11 infusions), non-hematological toxicity (four in-
fusions), and reasons other than toxicity (patients’ or inves-
tigators’ decision, 10 infusions). Chemotherapy was discon-
tinued early in 33 patients (65%) because of study treatment
toxicity (11 patients), disease progression or relapse (nine
patients), other reasons including adverse events not related
to study drugs (nine patients), patient’s request (two patients),
and death (two patients). The mean duration of treatment was
3.8 months. Dose intensity was analyzed on an ITT basis.
Mean ( SD) relative dose intensity for paclitaxel was 0.85
 0.15 and for carboplatin was 0.95  0.07.
Efficacy
Efficacy results based on the ITT population and on
reviewed data are summarized in Table 2. One complete (2%)
and 21 partial responses (41%) were reported by the expert
panel leading to an ORR of 43% (95% CI, 30%–57%). The
response rate according to investigators’ analyses was con-
gruent, giving an ORR of 41% (95% CI, 28%–55%; 1
complete response and 20 partial responses). The median
time to response was 1.87 months, and median progression-
free survival was 7.49 months. Panel reviews were not
conducted until progression of patients. Therefore, all data
were based on panel assessments, except for progression-free
survival, which was calculated using investigators’ assess-
ments (Figure 1).
Symptoms and Quality of Life
Symptoms and QoL changes over time are summarized
in Table 3. There was no significant change over time in the
total score (as defined by the average of the aggregate score
of all nine items).
Safety
The worst NCI-CTC toxicity grades experienced by
patients for the laboratory parameters are given in Table 4.
Myelosuppression was the most common toxicity. Neutrope-
nia was observed in 76.5% of patients; grade 3 or 4 was
observed in 39% of patients. One case of febrile neutropenia
was reported. Anemia was experienced by 84.3% of patients;
18% of patients experienced grade 3 anemia. No grade 4
anemia occurred. Thrombocytopenia was observed in 23.5%
of patients; grade 3 or 4 toxicity was observed in 8% of
patients. No hemorrhagic episode was reported. Abnormali-
ties of hepatic or renal functions were generally mild, revers-
ible, and not clinically relevant. However, one patient had a
grade 3 toxicity for creatinine without any clinical conse-
quence (Table 4).
Besides myelosupression, adverse events (AEs) possi-
bly or probably related to study drugs were usually mild in
severity and manageable. The most common related AEs
occurring during the study were alopecia (57% of patients),
fatigue (55%), nausea (41%), vomiting (24%), and constipa-
tion (20%). Grade 3 or 4 AEs were uncommon (Table 5) and
included grade 3 fatigue in six patients (12%), grade 3
constipation in two patients (4%), and grade 3 anorexia in
two patients (4%). Sensitive neuropathy (mainly reported as
paresthesia) affected up to 30% of the patients. Three patients
experienced grade 3 or 4 neuropathy: two grade 3 and one
grade 4. No death related to therapy occurred during the
study.
TABLE 2. Efficacy results based on reviewed data in the ITT
population
Number of
patients %
Best tumor response
Complete response 1 2
Partial response 21 41
Stable disease 15 29
Progressive disease 8 16
Unable to determine 5 10
Not evaluated 1 2
Overall best response rate (%) CRPR 43
95% CI 0.30–0.57
Time to response (mo) Median 1.87
95% CI 1.84–2.00
Progression-free survival (mo) Median 7.49
95% CI 6.21–9.43
Overall survival (mo) Median 13.63
95% CI 7.49–17.05
n  51.CI, confidence interval; CR, complete response; PR, partial response.All
data are based on panel assessment except for progression-free survival, which was
calculated using investigators’ assessment.
FIGURE 1. Overall survival. Probability of survival was esti-
mated by the Kaplan/Meier method.
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DISCUSSION
Among the different new anti-cancer agents that have
been approved in NSCLC chemotherapy, paclitaxel, gemcit-
abine, vinorelbine, and docetaxel share a better efficacy/
toxicity profile than older drugs. New drugs not only benefit
younger patients, but also offer new treatment opportunities
for the elderly. The benefit of chemotherapy for elderly
patients with NSCLC has been proved in a multicenter
controlled phase III study in which 191 patients older than 70
years with stage IIIB-IV NSCLC were randomized to vinorel-
bine or best supportive care.19 Vinorelbine produced a 19.7%
ORR and a longer median survival compared with best
supportive care (27 versus 21 weeks, respectively). This
survival benefit was corroborated by patient-reported out-
comes in which QoL had concomitantly improved. In the
recent Multicenter Italian Lung Cancer in the Elderly Study
large phase III trial including 707 elderly patients with
advanced NSCLC that compared single-agent chemotherapy
using either gemcitabine or vinorelbine versus a doublet
combination of both drugs, results showed no benefit in
response rate, time to progression, survival, and QoL for the
doublet combination.20 The response rates of the single-drug
chemotherapies or the non-platinum–based doublet chemo-
therapy regimens ranged from 15% to 22%, and the median
survival times ranged from 18 to 36 weeks. Nevertheless,
several recently published studies attempted to determine
safety and activity of specific platinum and taxanes combi-
nations in the elderly.13,21 Until now, no randomized study
has compared the efficacy and tolerability of standard plati-
num regimens with a single-drug regimen in elderly patients
with NSCLC.
We designed this phase II trial to evaluate the safety
and activity of a platinum-based doublet in elderly patients
with advanced NSCLC. The combination of weekly pacli-
taxel plus monthly carboplatin was effective as first-line
treatment with an ORR of 43%, median progression-free
survival of 7.5 months, and median overall survival of 13.6
months. The lack of random allocation versus current stan-
dard chemotherapies for elderly patients (i.e., single-drug
regimens) precluded a formal comparison with other sched-
ules of chemotherapy. In addition, the survival results were
given as a preliminary insight, as a longer follow up is
needed. Nevertheless, these results are in the range of what
could be expected for this disease, i.e., advanced and meta-
static NSCLC, even in younger patients. Other studies eval-
uating patient populations with a younger median age who
received a similar combination of weekly paclitaxel plus
monthly carboplatin provided similar results.13,22,23 In these
phase II studies, paclitaxel 70 mg/m2 given every week or
100 mg/m2 given weeks 1, 2, and 3 was combined with
carboplatin AUC 6 mg/ml-1/min given day 1 of a 4-week
schedule. ORRs ranged from 32% to 52%, and median
survival ranged from 11 to 14 months.13,22,23 As shown in
Table 1, the study was conducted in a population with a
median age of 74 years and ECOG PS 0 or 1 (only 10% of the
patients had a PS of 2). Therefore, the results observed in this
study mainly belong to a population of septuagenarian pa-
tients with good performance status.
Recently, two phase II studies investigated the efficacy
of low-dose weekly carboplatin (AUC 2 mg/ml-1/min) and
TABLE 3. Lung Cancer Symptom Scale questionnaire
Total scorea
Baseline End of cycle 1 End of cycle 2 End of cycle 3 End of cycle 4 End of cycle 5
n 51 51 46 37 31 24
Mean  SD 31.6  19.1 28.8  22.7 24.1  19.5 24.0  16.2 30.9  24.6 25.4  16.4
Median (range) 28.5 (2–72) 22.1 (3–100) 18.6 (0–73) 21.0 (3–70) 24.0 (3–100) 22.9 (4–58)
aAverage of the aggregate score of all nine items was used for the total score. Repeated measure analysis considering time as continuous: p  0.29. Repeated measure analysis
considering time as discrete: p  0.52.
TABLE 4. Worst NCI-CTC grade laboratory toxicities
Grade 1 Grade 2 Grade 3 Grade 4
n % n % n % n %
Hematology Leucopenia 6 12 17 33 14 27 1 2
Neutropenia 5 10 14 27 12 24 8 16
Thrombocytopenia 5 10 3 6 3 6 1 2
Anemia 11 22 23 45 9 18 0 0
Liver Transaminase 5 11 1 2 0 0 0 0
Bilirubin - - 4 9 0 0 0 0
Kidney Creatinine 4 8 3 6 1 2 0 0
TABLE 5. Grade 3 or 4 NCI-CTC non-hematological
toxicities
Grade 3 Grade 4
n % n %
Fatigue 6 12 — —
Constipation 2 4 — —
Anorexia 2 4 — —
Peripheral neuropathy 2 4 1 2
Nausea 1 2 — —
Stomatitis 1 2 — —
Vomiting 1 2 — —
Asthenia 1 2 — —
Back pain 1 2 — —
Urinary retention 1 2 — —
Dyspnea 1 2 — —
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paclitaxel (50 or 80 mg/m2) in elderly patients with advanced
NSCLC.24,25 Modest activity was observed in the Jatoi et al.
study (n 49) assessing paclitaxel 50 mg/m2 with an ORR of
14%.24 Better results were obtained in the Neubauer et al.
study (n 77) assessing paclitaxel 80 mg/m2 with an ORR of
38%, a median progression-free survival of 3.5 months, and
median survival of 7.2 months.25
As expected, the most common toxicity in this study
was myelosuppression, with grade 3 or 4 neutropenia occur-
ring in 39% of patients. However, grade 3 or 4 neutropenia
was transient and of short duration, leading to only one
episode of febrile neutropenia. Grade 3 or 4 thrombocytope-
nia occurred in few patients. Non-hematological toxicity
related to study treatment was manageable with no unex-
pected adverse events in this elderly population. Grade 3 or 4
toxicity was infrequent; fatigue was the most common grade
3 adverse event. Grade 3 or 4 peripheral neurotoxicity oc-
curred in three patients. Nevertheless, lower grade neurotox-
icity would have been more appropriately evaluated using a
neurophysiological examination and quantitative sensory
testing. This method able to detect early paclitaxel-induced
neuropathy was longitudinally evaluated in only one institu-
tion and could not be explored because of obvious subset
bias.26 Low-grade neuropathy is poorly evaluated in chemo-
therapy programs, although this long-lasting toxicity may
affect QoL, particularly in elderly patients frequently affected
by other neuropathy-induced comorbidities (e.g., diabetes
mellitus, respiratory deficiency). The good safety profile of
the paclitaxel-carboplatin combination in the elderly was also
reported in a Cancer and Leukemia Group B randomized
phase III study comparing paclitaxel alone versus this former
doublet.27 In this study, patients older than 70 years who had
received the doublet regimen achieved a higher response rate
and a longer progression-free survival than patients receiving
paclitaxel alone.
Is the proposed weekly paclitaxel and monthly carbo-
platin schedule a progress in treatment of advanced NSCLC
in the elderly? The present study cannot definitively answer
to this question because of its phase II design. However,
activity, safety profile, and QoL could be considered clues
favoring the feasibility of this schedule in the elderly. What
would be the comparator to be chosen in a further phase III
design? Taking into account data regarding cisplatin-based
chemotherapy, such as those described in the Kubota et al.
study,28 i.e., vindesine plus cisplatin or mitomycin, vindesine
plus cisplatin, or etoposide plus cisplatin alternating with
vindesine plus cisplatin, one can stress the fact that a classical
cisplatin-based regimen encountered safety limitations in
elderly patients. Studies specifically addressing the case of
modern cisplatin-based doublets (cisplatin plus a third-gen-
eration drug) in the elderly are still lacking, and data obtained
by subset analyses of patients older than 70 years in large
randomized studies might be interpreted with caution as they
include patients aged 70 to 75 years, rather than a general
elderly population. Therefore, the current American Society
of Clinical Oncology guidelines recommend the use of sin-
gle-agent chemotherapy for elderly patients or patients with
ECOG/Zubrod PS 2.29 A single-drug regimen such as that
validated in the ELVIS study19 would probably be the best
comparator to evaluate the role of weekly paclitaxel plus
monthly carboplatin combination in elderly patients.
Because of the modest survival improvement induced
by chemotherapy in advanced NSCLC, particularly in the
elderly, patient-reported outcome, especially QoL, must be
taken into account when evaluating a clinical benefit. In this
study, the use of a lung cancer-specific QoL scale (LCSS)
showed that the paclitaxel and carboplatin regimen could be
administered with reasonable maintenance of QoL during
therapy in elderly. However, these data must be cautiously
interpreted: (a) the phase II nature of the study introduces a
risk of overestimation of the QoL; (b) patient attrition from
QoL evaluation along the chemotherapy program mainly
affected those patients with poor response to therapy, patients
who encountered adverse events, and/or patients for whom
the disease progressed; and (c) patients lost to follow up from
QoL evaluation are usually those with poorest QoL at base-
line. In addition, it has been suggested that improved QoL
results during phase II studies may be linked to either study
agents or standard palliation and could cause overestimation
of clinical benefit.30
The application of NSCLC guidelines29 is a milestone
in epidemiological observation and knowledge of the disease
prognostic evolution. However, daily practice suggests that
accounting for comorbidities in therapeutic decisions could
be of paramount importance. Comorbid conditions are fre-
quent in NSCLC patient populations, especially considering
the high frequency of smokers in this population, and the
comorbidity scores increase with age. Comorbidities are an
important prognostic factor in patients with NSCLC and
might therefore be included in the pretherapeutic evaluation
in further studies.31
We conclude that only a phase III study with careful
QoL assessment comparing two different approaches of che-
motherapy; i.e., a single-drug regimen versus the platinum-
based schedule described in this study, could determine
whether this doublet regimen improved clinical benefit in the
elderly patients with NSCLC. The weekly paclitaxel plus
monthly carboplatin as an active regimen in elderly patients
deserves further study to compare this approach versus the
standard of care in this population.
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